corporate_fare

Spyre Therapeutics Inc.

Address: 221 Crescent Street Building 23 Suite 105

Sponsor Overview

assignment

Specializations

Rheumatologic Disease

Clinical research in rheumatology focuses on adults with moderately to severely active inflammatory disease, including rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis.

Disease activity reduction
Joint inflammation
Functional symptom control

These studies assess clinical response using established measures of arthritis severity and inflammatory burden.

Ulcerative Colitis

The sponsor’s gastroenterology portfolio includes moderate to severe ulcerative colitis, with interest in both histologic improvement and clinical remission.

Colonic inflammation
Mucosal healing
Remission outcomes

Research activity is centered on controlling intestinal disease activity in adults with active inflammatory bowel disease.

Inflammatory Disease Activity Assessment

Across its trials, the sponsor emphasizes validated clinical endpoints that capture changes in inflammatory disease activity in both musculoskeletal and gastrointestinal disorders.

Clinical remission
Symptom burden
Objective disease scoring

These areas reflect a focus on conditions where persistent inflammation drives ongoing tissue damage and patient disability.

Immune-Mediated Therapeutics

The clinical program is situated within immune-mediated disease research, spanning both rheumatologic and intestinal therapeutic domains.

Autoimmune inflammation
Targeted biologic therapy
Chronic inflammatory disorders

Research sites across multiple countries are engaged in evaluating treatments for active disease in these therapeutic areas.

Trial Name	Country	Status
Long‑Term Safety and Efficacy of SPY001‑001 Monotherapy and Combination Therapy with Long‑Acting Antibodies in Adults with Ulcerative Colitis	Austria Belgium Bulgaria Croatia Czechia France Germany Greece Hungary Italy Lithuania Poland Romania Slovakia Spain	Recruiting
Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis	Austria Belgium Bulgaria Croatia Czechia France Germany Greece Hungary Italy Lithuania Poland Romania Slovakia Spain The Netherlands	Recruiting
Phase 2 Study to Assess the Efficacy and Safety of SPY002-072 in Adults with Moderately to Severely Active Rheumatologic Disease	Bulgaria Czechia Poland Spain	Not Recruiting